Our results raised a possibility that Dukes' stage C CRC patients with tumors carrying TP53 mutation, especially the P72 allele, benefited most from 5-FU based postoperative chemotherapy, but we need to collect more CRC cases to form definite conclusions. This evidence concerns the gene TP53 and colorectal carcinoma.